Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole in Recurrent IDH Wild-Type Glioblastoma
NCT06552260Phase 1Recruiting
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of troriluzole in glioblastoma (GBM) (2 arms). Primary endpoint: High-gamma band power via electrocorticography. Started Feb 2025; status: recruiting.
02
Drugs
troriluzole
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06552260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552260.